ANNX - Annexon, Inc. Stock Price and Quote

Index	-	P/E	-	EPS (ttm)	-2.47	Insider Own	0.10%	Shs Outstand	73.86M	Perf Week	-51.69%
Market Cap	111.49M	Forward P/E	-	EPS next Y	-2.17	Insider Trans	-	Shs Float	46.49M	Perf Month	-47.51%
Income	-145.30M	PEG	-	EPS next Q	-0.54	Inst Own	100.70%	Short Float / Ratio	4.39% / 3.11	Perf Quarter	-47.22%
Sales	-	P/S	-	EPS this Y	23.70%	Inst Trans	29.93%	Short Interest	2.04M	Perf Half Y	-50.86%
Book/sh	2.91	P/B	0.98	EPS next Y	0.90%	ROA	-53.40%	Target Price	17.00	Perf Year	-7.77%
Cash/sh	5.83	P/C	0.49	EPS next 5Y	38.60%	ROE	-66.40%	52W Range	2.07 - 7.65	Perf YTD	-44.87%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-62.75%	Beta	-
Dividend %	-	Quick Ratio	10.10	Sales past 5Y	-	Gross Margin	-	52W Low	37.68%	ATR	0.64
Employees	80	Current Ratio	10.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	31.05	Volatility	20.76% 11.12%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	42.90%	Profit Margin	-	Rel Volume	9.83	Prev Close	2.10
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	656.26K	Price	2.85
Recom	1.70	SMA20	-46.99%	SMA50	-41.18%	SMA200	-48.19%	Volume	6,448,057	Change	35.71%

Date	Action	Analyst	Rating Change	Price Target Change
May-26-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $3
May-25-23	Downgrade	JP Morgan	Overweight → Neutral	$19 → $9
Sep-16-22	Initiated	Jefferies	Buy	$12
Sep-09-22	Initiated	BTIG Research	Buy	$15
Nov-30-21	Initiated	H.C. Wainwright	Buy	$40
Sep-23-21	Initiated	Cantor Fitzgerald	Overweight	$40
Jan-26-21	Initiated	Needham	Buy	$37
Aug-18-20	Initiated	JP Morgan	Overweight	$33
Aug-18-20	Initiated	Cowen	Outperform
Aug-18-20	Initiated	BofA Securities	Buy	$33

May-26-23 03:05AM	4 big analyst cuts: Snowflake downgraded twice on guidance miss (Investing.com) +35.71%
May-25-23 11:52AM	Why Shares of Annexon Are Plummeting Thursday (Motley Fool) -59.38%
10:12AM	Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study (Benzinga)
May-24-23 04:01PM	Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function (GlobeNewswire) -7.84%
May-16-23 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:01PM	Loading…
May-08-23 04:01PM	Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress (GlobeNewswire)
Apr-11-23 06:30AM	Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +5.95%
Mar-25-23 08:04AM	One Annexon, Inc. (NASDAQ:ANNX) insider upped their stake by 59% in the previous year (Simply Wall St.)
Mar-06-23 06:30AM	Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones (GlobeNewswire) -6.77%
Feb-27-23 06:30AM	Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference (GlobeNewswire)
Feb-16-23 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-12-23 07:35AM	Annexon, Inc.'s (NASDAQ:ANNX) Intrinsic Value Is Potentially 27% Above Its Share Price (Simply Wall St.)
Jan-17-23 04:30PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-23 09:00AM	Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises (GlobeNewswire)
Jan-06-23 06:30AM	Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio (GlobeNewswire) +5.29%
06:30AM	Loading…
Jan-04-23 06:30AM	Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-01-22 09:55AM	Wall Street Analysts Think Annexon, Inc. (ANNX) Could Surge 241%: Read This Before Placing a Bet (Zacks)
Nov-21-22 06:13AM	We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate (Simply Wall St.)
Nov-17-22 04:01PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-15-22 09:55AM	How Much Upside is Left in Annexon, Inc. (ANNX)? Wall Street Analysts Think 246% (Zacks)
Nov-03-22 06:30AM	Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023 (GlobeNewswire)
Oct-18-22 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-11-22 07:01AM	A Annexon, Inc. (NASDAQ:ANNX) insider increased their holdings by 59% last year (Simply Wall St.)
Sep-16-22 04:01PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-01-22 05:56PM	Amid Huntington's disease hopes and failures, Annexon targets new approach (American City Business Journals)
Aug-17-22 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-22 04:01PM	Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-11-22 06:25PM	Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025 (GlobeNewswire) -13.88%
Jul-08-22 07:00AM	Annexon Announces $130 Million Private Placement Financing (GlobeNewswire) +14.36%
Jun-07-22 12:19PM	Annexon Touts Final Huntington's Trial Data Confirming No New Safety Issues (Benzinga) +24.92%
06:30AM	Loading…
06:30AM	Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntingtons Disease (GlobeNewswire)
Jun-02-22 06:30AM	Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
Jun-01-22 07:30AM	Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings (GlobeNewswire) -5.10%
May-09-22 04:01PM	Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-05-22 06:30AM	Annexon Biosciences to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-21-22 06:02AM	Insider Buying: The Annexon, Inc. (NASDAQ:ANNX) CEO, President & Director Just Bought 59% More Shares (Simply Wall St.) -5.86%
Apr-18-22 10:35AM	Is Annexon (NASDAQ:ANNX) In A Good Position To Invest In Growth? (Simply Wall St.)
Apr-07-22 06:30AM	Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy (GlobeNewswire) -5.34%
Apr-04-22 06:30AM	Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire) +15.41%
Mar-03-22 04:01PM	Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntingtons Disease at AAN 2022 (GlobeNewswire)
Mar-01-22 04:01PM	Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Feb-28-22 06:30AM	Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference (GlobeNewswire) -5.54%
Jan-20-22 06:30AM	Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors (GlobeNewswire)
Jan-05-22 05:10PM	Why Annexon Biosciences Stock Plummeted 34% Today (Motley Fool) -34.06%
06:33AM	Annexon's Interim Mid-Stage Results On Huntington's Disease Candidate Fails To Cheer (Benzinga)
Jan-04-22 04:05PM	Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntingtons Disease Following Six-Month Treatment (GlobeNewswire) -7.79%
06:30AM	Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-31-21 08:30AM	Do Options Traders Know Something About Annexon (ANNX) Stock We Don't? (Zacks)
Dec-13-21 09:00AM	Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition (GlobeNewswire) -6.15%
Nov-30-21 05:24AM	10 Pharmaceutical Stocks to Buy Under $20 According to Jeremy Greens Redmile Group (Insider Monkey) +15.12%
Nov-28-21 11:17AM	3 Strong Buy Stocks for Bottom-Fishing Investors (TipRanks)
Nov-09-21 04:01PM	Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Oct-19-21 06:38AM	We're Not Very Worried About Annexon's (NASDAQ:ANNX) Cash Burn Rate (Simply Wall St.)
Oct-04-21 10:49AM	Annexon, Inc. (ANNX): Hedge Fund Sentiment Unchanged (Insider Monkey)
06:30AM	Annexon Biosciences Further Strengthens Its Executive Leadership Team With Appointment of Ted Yednock, Ph.D., to Chief Innovation Officer and Appointment of Larry Mattheakis, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Sep-23-21 06:30AM	Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference (GlobeNewswire)
Sep-20-21 06:30AM	Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event (GlobeNewswire)
Sep-16-21 11:30AM	EVP And Chief Scientific Officer Of Annexon Trades $351.08 Thousand In Company Stock (Benzinga)
Aug-16-21 04:01PM	Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update (GlobeNewswire)
Jul-22-21 07:00AM	Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases (GlobeNewswire)
May-21-21 06:30AM	Moving Average Crossover Alert: Annexon (ANNX) (Zacks)
May-17-21 04:05PM	Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results (GlobeNewswire)
May-05-21 07:00AM	Annexon to Present at the BofA Securities 2021 Virtual Healthcare Conference (GlobeNewswire)
Apr-22-21 01:47AM	Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-25-21 07:00AM	Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business Highlights (GlobeNewswire)
Mar-01-21 01:11PM	Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder Therapy (Benzinga)
07:00AM	Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy (GlobeNewswire)
Feb-08-21 07:00AM	Annexon Welcomes William H. Carson, M.D. to the Board of Directors (GlobeNewswire) +8.18%
Jan-12-21 07:00AM	Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Complement Therapeutics (GlobeNewswire)
Jan-05-21 07:00AM	Annexon to Present at the J.P. Morgan 39th Annual Healthcare Conference (GlobeNewswire) -5.52%
Dec-21-20 07:00AM	Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome (GlobeNewswire) -9.21%
Dec-11-20 01:15PM	Is ANNX A Good Stock To Buy Now? (Insider Monkey)
Nov-16-20 04:01PM	Annexon Biosciences Reports Third Quarter 2020 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-12-20 04:05PM	Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntingtons Disease Clinical Program (GlobeNewswire)
Oct-24-20 10:13AM	We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely (Simply Wall St.)
Sep-08-20 04:01PM	Annexon Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights (GlobeNewswire)
Jul-30-20 08:00AM	Annexon Biosciences Expands Leadership Team with the Appointment of Michael Overdorf as Chief Business Officer (GlobeNewswire)
Jul-28-20 04:05PM	Annexon Announces Closing of Initial Public Offering (GlobeNewswire)

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barre syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Love Douglas	President & CEO	Feb 15	Sale	5.87	6,571	38,564	197,646	Feb 17 05:12 PM
Lew Jennifer	EVP & Chief Financial Officer	Feb 14	Sale	6.30	166	1,046	29,542	Feb 15 06:59 PM
Overdorf Michael	EVP & Chief Business Officer	Feb 14	Sale	6.30	144	907	27,805	Feb 15 07:00 PM
Lew Jennifer	EVP & Chief Financial Officer	Feb 13	Sale	6.31	1,742	10,989	29,708	Feb 15 06:59 PM
Overdorf Michael	EVP & Chief Business Officer	Feb 13	Sale	6.30	1,501	9,461	27,949	Feb 15 07:00 PM
Satter Muneer A	Director	Feb 10	Buy	6.80	2,647,058	17,999,994	7,056,024	Feb 14 04:31 PM
Satter Muneer A	Director	Jul 07	Buy	3.84	2,453,988	9,423,314	4,408,966	Jul 11 08:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience